Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
4581 results about "Piperidine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Piperidine is an organic compound with the molecular formula (CH₂)₅NH. This heterocyclic amine consists of a six-membered ring containing five methylene bridges (–CH₂–) and one amine bridge (–NH–). It is a colorless liquid with an odor described as objectionable, and typical of amines. The name comes from the genus name Piper, which is the Latin word for pepper. Although piperidine is a common organic compound, it is best known as a representative structure element within many pharmaceuticals and alkaloids, such as natural-occurring solenopsins.
Methods and compositions for the treatment and management of hemoglobinopathy and anemia
InactiveUS20050143420A1Good effectRelieve symptomsBiocidePeptide/protein ingredientsRed blood cellThalassemia
The present invention is directed to the use of immunomodulatory compounds, particularly members of the class of compounds known as IMiDs™, and more specifically the compounds 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione and 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione, to induce the expression of fetal hemoglobin genes, genes essential for erythropoiesis, and genes encoding alpha hemoglobin stabilizing protein, within a population of CD34+ cells. These compounds are used to treat hemoglobinopathies such as sickle cell anemia or β-thalassemia, or anemias caused by disease, surgery, accident, or the introduction or ingestion of toxins, poisons or drugs.
Owner:SIGNAL PHARMA LLC
N-substituted piperidines and their use as pharrmaceuticals
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and / or diseases associated with aldosterone excess.
Owner:INCYTE HLDG CORP
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
Owner:CELGENE CORP
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
InactiveUS20060030594A1Prevent proliferationBiocidePeptide/protein ingredientsCompound (substance)Radiation therapy
Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
Owner:CELGENE CORP
Method for the oxidation of aldehydes, hemiacetals and primary alcohols
InactiveUS6498269B1Economical and effectiveGuaranteed economic efficiencySugar derivativesOrganic compound preparationHalogenBromine
A method for the oxidation of substrates comprising treating an aqueous, basic solution of a substrate having an oxidizable functionality using an elemental halogen as terminal oxidant in the presence of an oxoammonium catalyst / halide co-catalyst system. Use of elemental halogen, preferably chlorine gas or elemental bromine, unexpectedly allows oxidation without significant degradation of the substrate. The substrate is preferably a monosaccharide, oligosaccharide, or polysaccharide, and the oxidizable functionality is preferably an aldehyde, hemiacetal, or a primary alcohol. An effective source of the oxoammonium catalyst is 2,2,6,6-tetramethylpiperidinyl-1-oxy (TEMPO) and a particularly economical and effective catalyst is 4-acetylamino-2,2,6,6-tetramethylpiperidinyl-1-oxy.
Owner:UNIV OF CONNECTICUT
Prodrugs of piperazine and substituted piperidine antiviral agents
Owner:VIIV HEALTHCARE UK (NO 4) LTD
Substituted Piperidines that Increase P53 Activity and the Uses Thereof
In its many embodiments, the present invention discloses novel compounds, as inhibitors of HDM2 protein, methods for preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of treatment, prevention, inhibition, of one or more diseases associated with the HDM2 protein or P53 using such compounds or pharmaceutical compositions.
Owner:MERCK SHARP & DOHME LLC
Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS. The compounds of the invention for the general Formula I: wherein: Z is Q is selected from the group consisting of: -W- is
Owner:VIIV HEALTHCARE UK (NO 5) LTD
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Owner:CELGENE CORP
Method for removing carbon dioxide from combustion exhaust gas
InactiveUS6036931AHigh absorption rateImprove absorption rateDispersed particle separationHydrogen sulfides2-methylaminoethanolMorpholine
There are disclosed a method for removing CO2 from a combustion exhaust gas which comprises the step of bringing the combustion exhaust gas under atmospheric pressure into contact with an aqueous solution of a hindered amine selected from the group consisting of 2-amino-2-methyl-1-propanol, 2-methylaminoethanol, 2-ethylaminoethanol and 2-piperidineethanol; and another method for removing carbon dioxide from a combustion exhaust gas which comprises the step of bringing the combustion exhaust gas under atmospheric pressure into contact with a mixed aqueous solution of 100 parts by weight of an amine compound (X) selected from the group consisting of 2-amino-2-methyl-1,3-propanediol, 2-amino-2-methyl-1-propanol, 2-amino-2-ethyl-1,3-propanediol, t-butyldiethanolamine and 2-amino-2-hydroxymethyl-1,3-propanediol; and 1-25 parts by weight of an amine compound (Y) selected from the group consisting of piperazine, piperidine, morpholine, glycine, 2-methylaminoethanol, 2-piperidineethanol and 2-ethylaminoethanol.
Owner:THE KANSAI ELECTRIC POWER CO +1
Macrolide antibiotics and treatment and prophylaxis of pasteurellosis using the same
ActiveUS6514946B1High antibacterial activityReduced activityAntibacterial agentsBiocideTreatment fieldAntibacterial activity
20,23-disubstituted mycaminosyltylonolide derivatives and use of the same in the field of the prophylaxis and treatment of pasteurellosis are disclosed. The di-substituents are peperidino optionally substituted with one or two methyl groups. The derivatives have selective antibacterial activity against Pasteurella.
Owner:ZH BISEIBUTSU KAGAKU KENYKU KAI
Method for preparing disubstituted piperidine and intermediates
ActiveUS20100197928A1Reduce functionOrganic chemistryBulk chemical productionL-Pyroglutamic AcidCarboxylic acid
The disclosure relates to a method for preparing a compound of formula (I), wherein P1 and P2 are groups protecting the carboxylic acid and oxyamine functions, starting from pyroglutamic acid (S). The disclosure also relates to novel intermediates.
Owner:FOREST LAB HLDG LTD
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Owner:CELGENE CORP
Method of enhancing bioavailability of fexofenadine and its derivatives
The present invention relates to a method of enhancing the bioavailability of a piperidinoalkanol antihistamine in a patient which comprises co-administering to said patient an effective antihistaminic amount of said piperidinoalkanol and an effective p-glycoprotein inhibiting amount of a p-glycoprotein inhibitor.
Owner:AVENTISUB II INC +1
Aminopiperidine derivatives, preparation thereof and therapeutic use thereof
The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment and in the prevention of obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.
Owner:SANOFI AVENTIS SA
Methods of preventing and treating gastrointestinal dysfunction
Methods of preventing and treating gastrointestinal dysfunction, particularly postoperative ileus and post-partum ileus, in a patient undergoing surgery or other biological stress by administering 4-aryl-piperidine derivatives are disclosed.
Owner:MERCK SHARP & DOHME LLC
Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione
This invention relates to racemic and stereomerically pure 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione, and prodrugs, salts and solvates thereof. Synthesis, methods of use, and pharmaceutical compositions of racemic and stereomerically pure 4-amino-2-(3-methyl-2,6-dioxo-piperidine-3-yl)-isoindole-1,3-dione, and prodrugs, salts and solvates thereof, are disclosed.
Owner:MULLER GEORGE W +1
Method for removing carbon dioxide from combustion exhaust gas
InactiveUS6500397B1Improve absorption rateHigh absorption rateHydrogen sulfidesDispersed particle separation2-methylaminoethanolMorpholine
Owner:THE KANSAI ELECTRIC POWER CO +1
Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
ActiveUS20120035246A1Easily and efficiently producedSuppress gene expressionOrganic active ingredientsSugar derivativesNucleotideSingle strand
Provided is a novel nucleic acid molecule that can be produced easily and efficiently and can inhibit the expression of a gene. The nucleic acid molecule is a single-stranded nucleic acid molecule including an expression inhibitory sequence that inhibits expression of a target gene. The single-stranded nucleic acid molecule includes: a region (X); a linker region (Lx); and a region (Xc). The linker region (Lx) is linked between the regions (Xc) and (Xc). The region (Xc) is complementary to the region (X). At least one of the regions (X) and (Xc) includes the expression inhibitory sequence. The linker region (Lx) has a non-nucleotide structure including at least one of a pyrrolidine skeleton and a piperidine skeleton. According to this single-stranded nucleic acid molecule, it is possible to inhibit the expression of the target gene.
Owner:BONAC CORP
Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
InactiveUS20080279821A1BiocideHydrocarbon active ingredientsSerine Protease InhibitorsProteinase activity
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Processes for producing cellulose nanofibers, cellulose oxidation catalysts and methods for oxidizing cellulose
The present invention aims to provide a process for producing cellulose nanofibers using a 4-hydroxy TEMPO derivative less expensive than TEMPO and a process capable of rapidly producing homogeneous cellulose nanofibers. Wood cellulose can be efficiently converted into nanofibers by a process for producing cellulose nanofibers comprising treating a cellulosic material with an oxidizing agent in water in the presence of a cellulose oxidation catalyst comprising an N-oxyl compound represented by formula 1 below:wherein R1 and R2 are each independently hydrogen or a C1-C6 straight or branched alkyl group; and(i) one of R4 or R5 is —OR, —OCOR or —OSO2R wherein R is a straight or branched carbon chain having 4 or less carbon atoms, and the other of R4 or R5 is hydrogen, and R3 and R6 are methyl, or(ii) R4 is hydrogen, and R5, R3 and R6 are taken together with a piperidine ring to form an aza-adamantane compound having formula 2 below:or a mixture thereof, and a compound selected from the group consisting of bromides, iodides and mixtures thereof to prepare oxidized cellulose, and microfibrillating the oxidized cellulose to convert it into nanofibers.
Owner:NIPPON PAPER IND CO LTD
Therapeutic agents useful for treating pain
A compound of formula: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Tetrahydropiperidyl Compound”); compositions comprising an effective amount of a Tetrahydropiperidyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Tetrahydropiperidyl Compound are disclosed herein.
Owner:PURDUE PHARMA LP
Heterocyclic compound and antitumor agent containing the same as active ingredient
The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components:wherein X represents nitrogen atom or CH; R1 represents CHnF3-n (wherein n is 1 or 2), hydroxy C1–C6 alkyl, NHR6 [wherein R6 represents hydrogen atom or COR (wherein R represents hydrogen atom, C1–C6 alkyl or C1–C6 alkoxy)]; R2 represents morpholino (which may be substituted with one to four C1–C6 alkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C1–C6 alkyl), oxazolidinyl (which may be substituted with one or two C1–C6 alkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; R3 and R4 each represent hydrogen atom or C1–C6 alkyl; and R5 represents hydrogen atom, amino or hydroxyl.
Owner:OHARA PHARMA
Modulators of dopamine neurotransmission
InactiveUS6903120B2Good effectImproved pharmacokinetic propertiesBiocideNervous disorderPharmaceutical drugDouble bond
New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R1 is OSO2CF3, OSO2CH3, SOR3, SO2R3, COR3, NO2, or CONHR3 and when X is CH or C R1 may also be CF3, CN, F, Cl, Br, or I; R2 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or —(CH2)—R4; R3 is a C1-C3 alkyl CF3, or N(R2)2; R4 is a C3-C6 cycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Fused heterocyclic compound
InactiveUS20100029619A1Superior ASK inhibitory activityBiocideNervous disorderEngineeringMethyl group
The present invention provides a compound represented by the formula (I):whereinring A is a ring which is optionally further substituted;R1 is a hydrogen atom or a substituent;R2 is a hydrogen atom or a substituent;R3 is a hydrogen atom or a substituent;R4 is a hydrogen atom or a substituent;R5 is a hydrogen atom or a substituent;R6 is a hydrogen atom or a substituent;X is ═N— or ═C(Z)- (Z is a hydrogen atom or a substituent);when X is ═C(Z)-, Z and R6 are optionally bonded to each other to form, together with the carbon atom bonded thereto, an optionally substituted ring,provided that when X is ═CH—, then R6 is not optionally substituted 2-piperidinyl, excluding N-imidazo[1,2-a]pyridin-2-yl-4-methyl-benzamide, N-imidazo[1,2-a]pyridin-2-yl-benzamide and N-(7-methylimidazo[1,2-a]pyridin-2-yl)-benzamide, or a salt thereof, and a pharmaceutical agent containing same.The compound of the present invention has an ASK1 inhibitory action, and is useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, inflammatory diseases and the like, and the like.
Owner:TAKEDA PHARMA CO LTD
Therapeutic uses of pungent botanicals and their related compounds
InactiveUS6063381AIncrease in sizeDramatic effectivenessBiocideUnknown materialsAntiinfective agentTopical treatment
PCT No. PCT / US93 / 04763 Sec. 371 Date Mar. 18, 1997 Sec. 102(e) Date Mar. 18, 1997 PCT Filed May 19, 1993 PCT Pub. No. WO93 / 23061 PCT Pub. Date Nov. 25, 1993A new class of general antiinfective agents extracted from pepper, ginger, and other plant species containing vanillyl and piperidine ring structures typical of the pungent principal found in pepper and ginger. The role of these structures, their attached hydrocarbons groups, and other agents found with the plant extract is demonstrated in the topical treatment of dermatophyte infections, tissue injuries, and abnormal proliferations of keratin.
Owner:STAGGS JEFF J
Methods for treating cutaneous lupus using aminoisoindoline compounds
Methods of treating cutaneous lupus in a human are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione (ACTIMID™), 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (REVLIMID®), or cyclopropyl 2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide, alone or alternatively, in combination with a second active agent.
Owner:CELGENE CORP
Novel piperidine compound and drugs containing the same
The present invention provides a novel compound having a superior Na<+> channel inhibition activity. Namely, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, the ring A represents a ring represented by the formula: (wherein R<1 >represents a hydrogen atom etc.; and R<2 >represents indicates a hydrogen atom and the like) etc.; W represents an optionally substituted C1-6 alkylene group etc.; Z represents an optionally substituted C6-14 aromatic hydrocarbon cyclic group etc.; and l represents an integer from 0 to 6.
Owner:EISIA R&D MANAGEMENT CO LTD
1-(4-arylpiperazin-1-yl)- omega -[n-( alpha . omega -dicarboximido)]-alkanes useful as uro-selective alpha 1-adrenoceptor blockers
Novel piperzine derivatives substituted on one nitrogen by an aromatic system and on the other nitrogen by (2,5-dioxopyrrolidin)-1-yl) alkanes or (2,6-dioxopiperidin-1-yl) alkanes have been found to exhibit selective alpha 1A adrenergic activity. The compounds are useful for treatment of disease conditions, such as peripheral vascular disease, congestive heart failure, hypertension and especially benign prostatic hypertrophy.
Owner:RANBAXY LAB LTD
Potent inducers of terminal differentiation and methods of use thereof
The present invention provides the compound having the structure: ##STR1## wherein each of R.sub.1 and R.sub.2 are independently the same as or different from each other; when R.sub.1 and R.sub.2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R.sub.1 and R.sub.2 are different, R.sub.1 =R.sub.3 --N--R.sub.4, wherein each of R.sub.3 and R.sub.4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R.sub.3 and R.sub.4 bond together to form a piperidine group and R.sub.2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8. The present invention also provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition and a therapeutically acceptable amount of the compound above.
Owner:SLOAN KETTERING INST FOR CANCER RES +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com